Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2019 11:19 ET | Source: Immutep Limited

Immutep to Host Eftilagimod Alpha Clinical Development Update Global Webcast

SYDNEY, Australia, March 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
March 21, 2019 18:10 ET | Source: Immutep Limited

Immutep Announces United States Patent Grant for Eftilagimod Alpha in Cancer

SYDNEY, Australia, March 21, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
March 18, 2019 19:07 ET | Source: Immutep Limited

Immutep to Present IMP761 Preclinical Results in Global Webcast

SYDNEY, Australia, March 18, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
March 07, 2019 16:30 ET | Source: Immutep Limited

Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation

SYDNEY, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer...
March 06, 2019 08:00 ET | Source: Immutep Limited

Immutep Announces Data from Ongoing TACTI-mel Phase I Clinical Trial in Unresectable or Metastatic Melanoma

Presented at the World Immunotherapy Congress USA 2019 SYDNEY, Australia, March 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology...
March 06, 2019 08:00 ET | Source: Immutep Limited

Immutep doses First Patient in TACTI-002 Phase II Trial

The First Patient has been dosed at “START Madrid- FJD” in SpainClinical trial sites are active and more will be activated and commence recruitment in coming months SYDNEY, Australia, March 06, 2019...
March 04, 2019 08:00 ET | Source: Immutep Limited

Immutep to Present at Oppenheimer’s 29th Annual Healthcare Conference

SYDNEY, Australia, March 04, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer...
February 26, 2019 08:00 ET | Source: Immutep Limited

Immutep to Present at Upcoming Industry Conferences

SYDNEY, Australia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer...
January 07, 2019 08:00 ET | Source: Immutep Limited

Immutep Enters Into Clinical Trial Collaboration, Service and Supply Agreement With CYTLIMIC

New clinical trial collaboration with CYTLIMIC to test eftilagimod alpha (“efti” or “IMP321”) as part of a cancer peptide vaccine discovered by artificial intelligenceBuilds on Immutep’s longstanding...
December 19, 2018 07:00 ET | Source: Immutep Limited

Immutep Announces US$5.2 Million Financing Led by U.S. Specialist Healthcare Investor, Altium Capital

Extends the Company’s cash runway into mid-2020, during which time Immutep is expected to report meaningful clinical data SYDNEY, Australia, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:...